clinical trial · NCT04344158
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase3·active not recruiting·n = 648
Advanced Hepatocellular Carcinoma (HCC)AK105 InjectionAnlotinib Hydrochloride CapsulesSorafenib Tosylate Tablets
brief summary
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus Sorafenib. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or Sorafenib, with 2:1 random ratio. Every 21 days is a treatment cycle.
started
Aug 11, 2020
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Feb 20, 2025
official title
A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol